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Abstract
Purpose To assess the effectiveness of a preventive
health program and vitamin D status in improving the
health-related quality of life (HRQOL) of older residents of
Canada.
Design We analyzed baseline and follow-up data of 2119
volunteers of a community program that promotes healthy
lifestyles and encourages vitamin D supplementation. We
examined the program effect on each of the five dimen-
sions of the EQ-5D-5L, HRQOL score, and quality-ad-
justed life years (QALYs) using multivariable regression
methods. We further examined the specific contribution of
vitamin D status as quantified by serum 25-hydroxyvitamin
D (25(OH)D).
Results Problems with mobility, usual activities, pain/
discomfort, and depression/anxiety were reported less
during follow-up compared to baseline. On average, par-
ticipants’ HRQOL had improved by 0.018 units at
6 months and 0.025 units at 1 year of follow-up.
Improvements in vitamin D status were independently
associated with improvements in HRQOL and in QALYs.
As per 25 nmol/L increase in 25(OH)D, there was a 0.002
increase in HRQOL and a 0.001 increase in QALYs.
Conclusions This study documents the benefits of a real-
world preventive health program to HRQOL. It is the first
to reveal that improvements in vitamin D status parallel
improvements in HRQOL among healthy community
dwellers. The study further suggests that the preventive
health program and supplementation with vitamin D are
cost-effective interventions.
Keywords Health-related quality of life  Vitamin D 
Public health  Disease prevention  Intervention  Nutrition
Introduction
Vitamin D has been shown to benefit bone health and to
reduce the burden of various diseases [1]. To mediate the
health benefits, the Institute of Medicine and Health
Canada recommend a vitamin D intake of 600 IU per day
for adults and 800 IU per day for those above the age of
70 years [2,3]. These intakes are assumed to be sufficient
to achieve an adequate serum 25-hydroxyvitamin D
(25(OH)D) concentration, the established measure of
vitamin D status. However, recent studies have suggested
that the intake needed to achieve an adequate vitamin D
status varies by weight status [4–6].
In Canada, diets contribute an estimated 232 IU of
vitamin D per day [7] and, given its Northern latitude,
cutaneous synthesis of vitamin D by sun exposure is lim-
ited [8]. Despite the Health Canada recommendations,
vitamin D deficiency and insufficiency continue to be
prevalent [9]. Specifically, the Canadian Health Measures
Survey had shown that 4.1 and 10.6 % of Canadians aged
6–79 years had serum 25(OH)D concentrations of less than
27.5 and 37.5 nmol/L, respectively [9].
For older populations, several vitamin D supplementa-
tion studies have suggested, though not consistently, less
functional limitation [10], prevention of falls [11–13],
reductions in fractures [14–16], and benefits to mental
health [17, 18]. Based on a meta-analysis, Bischoff-Ferrari
et al. [12] had recommended vitamin D supplementation to
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achieve a reduction in falls. The above studies suggest a
relationship between vitamin D and objectively measured
health conditions. Health-related quality of life (HRQOL)
aims to quantify the subjective experiences of the conse-
quences of these health conditions. Huang et al. attributed
improvements in quality of life along with improvements
in pain and sleep to vitamin D supplementation in a case
series of patients with chronic pain [19]. For a cross-sec-
tional sample of older healthy volunteers, we recently
showed that vitamin D status was positively associated
with HRQOL [20]. In the latter study, we acknowledged
the issue of reverse causality and recommended that
intervention studies are needed to show whether vitamin D
supplementation leads to improvements in HRQOL [20].
In the present study, we examine the effect of a pre-
ventive health program that encourages vitamin D sup-
plementation on HRQOL among older residents of Canada.
This seems particularly important to Canadians given the
relatively high latitude and consequent reliance on vitamin
D from diet and supplements.
Methods
This is a real-world evaluation of information gathered at
baseline and follow-up visits from volunteer participants of
a preventive health program by the Pure North S’Energy
Foundation (PN). PN, a charitable, not-for-profit organi-
zation, provides lifestyle counseling and encourages vita-
min D and multivitamin supplementation as described in
more detail elsewhere [21–23]. As of August of 2012, PN
started the recruitment of older residents of the city of
Calgary, Alberta, Canada. PN advertised their program for
seniors through local newsletters and through the distri-
bution of flyers in senior homes and community centers.
PN organized weekly information meetings after which
attendees could elect to sign up to enroll in the program. At
their baseline and follow-up visits, participants completed a
survey, had their body height and weight measured, and
had their blood drawn for the assessment of serum
25-hydroxyvitamin D (25(OH)D), a measure of vitamin D
status. Until April 2013, 25(OH)D was measured with the
Liaison (chemiluminescent reaction) and, after that with a
liquid chromatography, tandem mass spectrometry (LC/
MS–MS) method. The correlation for 25(OH)D between
methods was 0.801 (n = 3015, p\ 0.001).
The survey included the five-level EQ-5D (EQ-5D-5L)
to measure health-related quality of life (HRQOL) [24].
The EQ-5D consists of a five-dimensional descriptive
system asking whether participants have (1) no problems;
(2) slight problems; (3) moderate problems; (4) severe
problems; or (5) extreme conditions or are unable to per-
form, or extreme conditions are fully constrained or
restricted, with each of the following: (1) mobility; (2) self-
care; (3) usual activities; (4) pain or discomfort; and (5)
anxiety or depression [24]. HRQOL scores are based on
responses to each of the five dimensions and were derived
from the US value sets [25]. The EQ-5D is an established
and validated instrument [24] with the major advantages of
being short and easy to complete [26].
The survey further included questions on age, gender,
perceived health, and income. Individuals and couples with
an annual income of less than $25,000 and of less than
$41,000, respectively [27], were considered as low income.
Body mass index (BMI) was calculated on the basis of the
measured heights and weights (weights in kilograms divi-
ded by the square of height in meters). Individuals with a
BMI of 25 or more were considered overweight, and those
with a BMI of 30 or more were considered obese [28].
Serum 25(OH)D is the established proxy for vitamin D
status. Some have suggested that individuals with serum
25(OH)D concentrations below 50 nmol/L should be con-
sidered vitamin D deficiency, and those with serum
25(OH)D concentrations of 50 or more and less than
75 nmol/L be considered vitamin D insufficiency [29]. As
recent studies have suggested extra-skeletal benefits, such
as reduction in colorectal cancer and cardiovascular disease
risk, for individuals with serum concentrations of 75 nmol/
L or more [1, 30, 31], and where sufficient number of
observations with serum concentrations above 75 nmol/L
are observed, we further categorized serum concentrations
into C75 and\100 nmol/L, C100 and\125 nmol/L, and
C125 nmol/L. Where the above categorizations of vitamin
D status provide some ease in interpretations, we did
confirm our analysis while considering vitamin D status as
a linear covariate.
As descriptive statistics we present the changes in the
reporting of problems in the five EQ-5D dimensions and in
the HRQOL score between baseline and 6 months of fol-
low-up and between baseline and 1 year of follow-up (also
referred to as temporal changes). The changes over
6 months of follow-up have the advantage of a larger
sample size, and the changes over 1 year of follow-up have
the advantage of longer intervention. We used a Chi-square
test to test for the significance of temporal changes in the
prevalence of problems and a one sample t test to test
whether the mean temporal changes in HRQOL score were
significantly different from zero. We applied univariate and
multivariable regression to identify determinants of the
temporal changes in HRQOL scores at 6 months and at
1 year. In addition to quantify the temporal changes at
6 months and at 1 year, we fitted an overall linear mixed-
effect model for changes in HRQOL over time in the
program using all observations regardless of when the
observation was made. In all multivariable regression
models, we adjusted for age, gender, body weight status,
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and baseline HRQOL. Furthermore, we examined the
importance of vitamin D status for temporal changes in
HRQOL scores by considering (1) the baseline serum
25(OH)D concentrations and (2) the difference between the
follow-up and baseline serum 25(OH)D concentrations
(also referred to as the temporal increase in serum
25(OH)D) as determinants of temporal changes in HRQOL
scores.
Quality-adjusted life years (QALY’s) were estimated by
the area under the HRQOL curve method [32].
PN anonymized their data prior to forwarding it to the
University of Alberta for statistical analysis. The analysis
was conducted using STATA version 12 (College Station,
Texas). The Human Research Ethics Board of the
University of Alberta approved the data access and analysis
for this study.
Results
A total of 2119 participants had both baseline and follow-
up assessments of HRQOL and serum 25(OH)D. Baseline
characteristics of the 2119 participants are presented in
Table 1. Of the 2119 participants, 1795 (84.7 %) and 761
(35.9 %) had follow-up assessments at 6 months
(4–8 months) and 1 year (9–15 months), respectively.
Temporal changes in the prevalence of problems in the
five EQ-5D dimensions and the HRQOL score are pre-
sented in Table 2. At the follow-up visits, participants
reported fewer problems with mobility, usual activities,
pain or discomfort, and depression or anxiety compared
with what they reported at baseline (Table 2). For the 1795
participants with follow-up assessments at 6 months, the
mean HRQOL score was 0.816 at baseline and 0.833 at
6-month follow-up, representing a temporal increase of
0.018 units in 6 months (Table 2). As a result, at 6 months
of follow-up, fewer participants would retain in the base-
line lower tertile and instead moved to the higher HRQOL
tertiles (Table 2). For the 761 participants with follow-up
assessments at 1 year, the mean HRQOL score was 0.808
at baseline and 0.832 at 1-year follow-up, representing a
temporal increase of 0.025 units in 1 year (Table 2). For
participants with follow-up at 1 year, the mean serum
25(OH)D concentration increased from 95 nmol/L at
baseline to 129 nmol/L at 1 year of follow-up. At baseline,
participants reportedly supplemented on average 2427 IU
of vitamin D per day. At one year, this was 7510 IU per
day.
Figure 1 and Table 3 show that temporal increases in
HRQOL scores during follow-up were more pronounced
among participants in the lowest tertile of baseline HRQOL
score compared to those in the higher tertiles. Table 3
further shows that gender, body weight status, and changes
in serum 25(OH)D were important and statistically sig-
nificant determinants of improvement in HRQOL at 1 year
of follow-up. The adjusted difference in mean temporal
change was estimated to be 0.060 units higher among
participants in the lowest relative to the highest tertile
(Table 3). Those participants who realized increases in
serum 25(OH)D of more than 50 nmol 25(OH)D/L had
mean-adjusted temporal change that were 0.024 units
higher as compared to those whose serum concentrations
did not increase (Table 3). As per 25 nmol/L increase in
25(OH)D, HRQOL increased by 0.005 units, after adjust-
ing for baseline HRQOL, baseline serum 25(OH)D, age,
and gender (Table 3). Further, male participants experi-
enced higher improvements in HRQOL compared to
female participants and participants with obesity experi-
enced lower improvements in HRQOL compared to normal
weight participants. At 6 month of follow-up, changes in
HRQOL were not statistically significantly different for
Table 1 Baseline characteristics of 2119 participants with a baseline
and follow-up assessments of HRQOL











Low income 1021 48.2
Baseline HRQOL 2119 0.814 0.118
Baseline serum 25(OH)D (nmol/L) 2119 93.449 35.916
Baseline serum 25(OH)D (nmol/L)
C50,\75 nmol/L 491 23.2
\25 nmol/L 11 0.5
C25,\50 nmol/L 135 6.4
C75,\100 nmol/L 722 34.1
C100,\125 nmol/L 447 21.1
C125 nmol/L 313 14.8
Baseline self-reported health
Very good or excellent 857 40.4
Good 798 37.7
Poor or fair 373 17.6
Baseline weight status
Underweight or normal weight 715 33.7
Overweight 796 37.6
Obesity 561 26.5
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weight status and increases in 25(OH)D but were different
for baseline HRQOL tertile and gender (Table 3).
When considering all determinants simultaneously, the
HRQOL score increased by 0.023 (95 % CI 0.018, 0.028)
per year (Table 4). When further considering vitamin D
supplementation doses, the estimates in Table 4 did not
substantially change. In addition, vitamin D supplementa-
tion dose had a minimal and not statistical significant effect
on HRQOL because of collinearity of vitamin D supple-
mentation doses and 25(OH)D concentrations and because
vitamin D status is on the causal pathway. The observed
increase of 0.023 in HRQOL per year translates into 0.012
QALYs gained per person per year. When change in
25(OH)D was added to the model, the effect of time in the
program reduced slightly from 0.023 to 0.020 units per
year and each 25 nmol/L increase in serum 25(OH)D was
associated with a 0.002 increase in HRQOL (Table 4). This
translates into 0.001 QALYs gained per 25 nmol/L
increase in serum 25(OH)D per person per year.
Discussion
This study revealed benefits of a real-world preventive
health program that encourages vitamin D supplementa-
tion. Problems with mobility, usual activities, pain or dis-
comfort, and depression or anxiety were all reported less at
follow-up as compared to baseline. Overall HRQOL and
QALYs gained during follow-up and paralleled improve-
ments in vitamin D status.
The present study showed improvements in mobility and
usual activities. This seems consistent with findings from
observational studies and clinical trials that had reported
benefits to mobility and functional status in terms of pre-
vention of falls [12] and improvement in physical function
[33]. A recent meta-analysis of randomized controlled tri-
als concluded that vitamin D supplementation among
unselected community-dwelling individuals may reduce
the risk of skeletal or non-skeletal outcomes to up to 15 %
[34]. In the present real-world evaluation, we observed
reductions of 5.2 and 8.3 % in the reporting of problems
Table 2 Changes in problems in EQ-5D dimensions, HRQOL score, serum 25(OH)D concentrations from baseline to 6 months and 1 year
Variable Temporal change from baseline to 6 months (N = 1795) Temporal change from baseline to 1 year (N = 761)
Baseline 6 months Change (95 % CI) p value Baseline 1 year Change (95 % CI) p value
Problems in EQ-5D dimensions (%)
Problems with mobility 39.2 35.2 -4.0 (-5.9, -2.0) 0.014 39.4 34.2 -5.3 (-8.5, -2.0) 0.033
Problems with self-care 6.2 6.8 ?0.6 (-0.6, 1.7) 0.499 7.1 5.7 -1.4 (-3.3, 0.4) 0.248
Problems with usual
activities
34.5 29.0 -5.5 (-11.5, -3.5) \0.001 35.9 27.6 -8.3 (-11.5, -5.0) \0.001
Problems with pain and
discomfort
76.7 67.9 -8.9 (-11.0, -6.7) \0.001 81.7 69.0 -12.7 (-16.0, -9.5) \0.001
Problems with depression
and anxiety
47.5 43.1 -4.5 (-6.6, -2.3) \0.001 51.9 43.8 -8.1 (-11.7, -4.6) 0.001
Any problem 85.1 78.7 -6.5 (-8.3, -4.6) 0.007 88.6 81.5 -7.1 (-9.9, -4.3) \0.001
Health-related quality of
life score, mean
0.816 0.833 0.017 (0.012, 0.021) \0.001 0.808 0.832 0.025 (0.018, 0.032) \0.001
Serum 25(OH)D nmol/L,
mean
93.0 130.8 37.8 (36.0, 39.6) \0.001 95.0 129.1 34.2 (31.2, 37.1) \0.001
Vitamin D supplementation
(IU), mean
2427 7510 5123 (4852, 5395) \0.001 2500 6725 4280 (3955, 4605) \0.001
Fig. 1 Temporal changes in HRQOL by baseline HRQOL tertile.
Note: Bubbles represent the mean HRQOL level at baseline, at
6 month, and at 1 year of follow-up. The size of the bubbles is
proportional to the number of assessments at each reporting time
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with mobility and with usual activities, respectively. The
very low prevalence of problems with self-care among
program participants may be causing a ceiling effect
whereby further improvements are difficult to achieve.
Vitamin D has also been shown to be associated with less
depression [17, 35] which seems consistent with our
Table 3 Determinants of temporal changes in HRQOL of program participants at 6 months (N = 1795) and 1 year (N = 761)
Variable Temporal change from baseline to 6 months
(N = 1795)







b p value b p value b p value b p value
Gender
Female (Ref.) 0.016 – – – – 0.021 – – – –
Male 0.019 0.003 0.531 0.010 0.030 0.032 0.011 0.142 0.016 0.020
Baseline age
50–59 0.024 – – – – 0.030 – – – –
60–69 0.012 -0.012 0.060 -0.007 0.264 0.025 -0.005 0.583 0.005 0.518
70–79 0.021 -0.003 0.716 0.001 0.906 0.020 -0.010 0.358 -0.001 0.912
80? 0.012 -0.012 0.264 -0.014 0.160 0.025 -0.005 0.799 -0.017 0.320
Baseline income
Other (Ref.) 0.013 – – – – 0.021 – – – –
Low income 0.020 0.007 0.148 -0.006 0.191 0.031 0.010 0.155 -0.005 0.478
Baseline serum 25(OH)D (100 nmol/L) – 0.001 0.937 0.007 0.307 – -0.018 0.056 -0.004 0.635
Baseline serum 25(OH)D (nmol/L)
\25 nmol/L 0.078 0.066 0.054 0.041 0.197 0.093 0.055 0.273 0.042 0.361
C25,\50 nmol/L 0.023 0.011 0.303 0.001 0.919 0.036 -0.002 0.874 -0.011 0.436
C50,\ 75 nmol/L (Ref.) 0.012 – – – – 0.038 – – – –
C75,\100 nmol/L 0.021 0.009 0.185 0.008 0.189 0.022 -0.016 0.115 -0.006 0.523
C100,\125 nmol/L 0.008 -0.004 0.590 -0.001 0.839 0.021 -0.017 0.106 -0.001 0.931
C125 nmol/L 0.023 0.011 0.182 0.012 0.125 0.010 -0.028 0.017 -0.018 0.098
Baseline HRQOL score – -0.303 \0.001 -0.307 \0.001 -0.354 \0.001 -0.362 \0.001
Baseline HRQOL tertile
Lowest HRQOL tertile (Ref.) 0.036 – – – – 0.054 – – – –
Middle HRQOL tertile 0.024 -0.013 0.033 -0.013 0.023 0.024 -0.030 \0.001 -0.031 \0.001
Highest HRQOL tertile -0.008 -0.045 \0.001 -0.045 \0.001 -0.005 -0.059 \0.001 -0.060 \0.001
Baseline self-reported health
Very good or excellent (Ref.) 0.014 – – – – 0.023 – – – –
Good 0.020 0.006 0.257 -0.018 \0.001 0.023 0.001 0.949 -0.025 0.001
Poor or fair 0.018 0.005 0.487 -0.049 \0.001 0.034 0.011 0.291 -0.047 \0.001
Baseline weight status
Underweight or normal weight (Ref.) 0.011 – – – – 0.024 – – – –
Overweight 0.019 0.008 0.156 0.002 0.702 0.027 0.003 0.755 -0.003 0.666
Obesity 0.018 0.007 0.274 -0.007 0.236 0.020 -0.004 0.661 -0.024 0.008
Change in serum 25(OH)D (per 25 nmol/L) – -0.001 0.604 0.001 0.509 – 0.005 0.031 0.005 0.020
Change in 25(OH)D
B0 (Ref.) 0.027 – – – – 0.017 – – – –
[0, B25 0.017 -0.010 0.240 -0.001 0.862 0.021 0.004 0.740 0.013 0.243
[25, B50 0.014 -0.013 0.105 -0.004 0.611 0.025 0.008 0.474 0.017 0.138
[50 0.015 -0.012 0.143 -0.002 0.837 0.033 0.015 0.160 0.024 0.036
Ref. reference category, 25(OH)D serum 25-hydroxyvitamin D concentrations
a Adjusted for age, gender, baseline HRQOL, and baseline 25(OH)D
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observation of a reduction in the reporting of problems
with depression and anxiety. Of all dimensions, the largest
reduction was reported for problems with ‘‘pain and dis-
comfort’’ that dropped from 81.7 to 69 % in the first year.
Bias by indication [36], whereby individuals with depres-
sion and anxiety and with pain and discomfort are more
likely to participate and comply with program recom-
mendations, may have contributed to a selective enroll-
ment. At enrollment, we observed higher proportions of
program participants reported problems with depression
and anxiety (48 vs 32 %) and pain and discomfort (77 vs
70 %) compared to the general population of Alberta in the
same age range [37].
As the present study is an evaluation of a real-world
program rather than a randomized controlled trial with a
strict protocol and blinded administration of the vitamin, it
is not possible to disentangle the benefits of vitamin D
supplementation from benefits of other program compo-
nents such as promotion of healthy eating, active living,
multivitamin use, and sun exposure. Therefore, and in light
of the health promotion focus of this program evaluation,
we had studied the importance of improving vitamin D
status as a distinct achievement of the program. The
regarding analyses revealed independent benefits to
HRQOL arising from improvements in vitamin D status
and from other program components.
The program effect translated into 0.012 QALYs gained
per person per year, and the vitamin D status effect into
0.001 QALYs gained per 25 nmol/L increase in serum
25(OH)D per person per year. Assuming costs of CA$30
for an annual supply of vitamin D supplements, the cost-
effectiveness ratio for someone who increases their vitamin
D status with 50 nmol/L would be CA$15,000 per QALY
($30 divided by 2 times 0.001 QALY). The costs of the
program in its pilot stage were estimated to range from CA
$900 to 1200 per participant per year and for a sustained
delivery of the scaled-up program CA $500 per participant
per year. The cost-effectiveness ratio for the program is
estimated to be CA$41,667 per QALY ($500/0.012
QALY). Both these ratios are considered cost-effective
according to Rocchi et al. [38] who considered ratios below
$50,000 per QALY as cost-effectiveness. In Canadian
dollars in 2008, this is CA$114,000 per QALY. Canada
and its provinces do not have an established cutoff
threshold levels for cost per QALY and have a practice of
considering other factors as well. A review of Canadian
Common Drug Review concluded that new drugs were
frequently accepted up to CA$80,000 per QALY though
also noted that this threshold was not consistently applied
[38]. Vitamin D supplementation is paid for by the indi-
vidual, and the PN program is charitable. But even if
vitamin D and the PN program were publicly funded, both
ratios (program and vitamin D) would be cost-effective as
the cost per QALY is in a range where most drugs are
accepted. Moreover, it is important to note that HRQOL
declines with age and the magnitude of this decline
increases with age [39, 40]. Hazall et al. had estimated this
natural (aging) decline in HRQOL to approximate 0.005
Table 4 Determinants of temporal changes in HRQOL among 2119 program participants
Variable Not including serum 25(OH)D With serum 25(OH)D included
b (95 % CI) p value b (95 % CI) p value
Years in program 0.023 (0.018, 0.028) \0.001 0.020 (0.014, 0.026) \0.001
Change in 25(OH)D (25 nmol/L) 0.002 (0.000, 0.004) 0.022
Baseline HRQOL -0.178 (-0.197, -0.159) \0.001 -0.179 (-0.198, -0.159) \0.001
Gender
Female (Ref.) – – –
Male 0.007 (0.003, 0.012) 0.002 0.007 (0.003, 0.012) 0.003
Baseline weight status
Underweight or normal weight (Ref.) – – – –
Overweight -0.001 (-0.006, 0.004) 0.716 -0.001 (-0.006, 0.004) 0.750
Obesity -0.008 (-0.014, -0.002) 0.008 -0.008 (-0.014, -0.002) 0.009
Baseline age
50–59 (Ref.) – – – –
60–69 -0.002 (-0.008, 0.004) 0.566 -0.002 (-0.008, 0.004) 0.538
70–79 -0.001 (-0.008, 0.006) 0.767 -0.001 (-0.008, 0.005) 0.730
80? -0.008 (-0.018, 0.002) 0.138 -0.008 (-0.018, 0.002) 0.123
Ref. reference category, 25(OH)D serum 25-hydroxyvitamin D concentration
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which translate in a reduction of 0.0025 QALY’s per per-
son per year [39]. If we had contrasted the observed
increases among program participants against the natural
decline in HRQOL and QALY’s resulting from aging, the
program and vitamin D benefits would have appeared even
more favorable and more cost-effective.
The average serum 25(OH)D concentration of program
participants was 93.4 nmol/L which is substantially higher
than the average among Canadians aged 6–79 (67.7 nmol/
L) and among Canadians 60–79 years of age (72.0 nmol/L)
[9]. Self-selection of health-aware individuals interested to
participate in the preventive health program may have
contributed to this. As vitamin D status is positively related
to HRQOL [20], and the present study revealed substantial
larger program benefits for participants in the lower
HRQOL tertile, one may expect larger benefits to similar
interventions in populations that are better representative of
Canadians. Where Health Canada recommendations apply
to the general Canadian population, no earlier study
reported on the benefits of improvements in vitamin D
status for the quality of life in a general population. Though
we conducted this in a community sample, caution is
warranted when it comes from generalizing our findings as
this sample may be self-selected toward a health-aware
subpopulation and with a relatively high prevalence of
problems with pain and discomfort [20]. Despite the large
sample size, a second study limitation relates to the small
number of participants that reported problems with self-
care, which hampered some of the analyses. Further limi-
tations relate to the limited duration of follow-up and the
study design. The present study evaluated a real-world
program. These results may therefore be particularly rele-
vant for public health decision makers, but we acknowl-
edged that stronger biological evidence comes from
randomized controlled trials. We therefore recommend
randomized controlled trials include pre- and post-inter-
vention assessments of HRQOL to strengthen the biologi-
cal evidence. A final limitation relates to the use of self-
reported information which is prone to error, though the
EQ-5D is an established and validated instrument [24]
whereby the reporting error is expected to be limited given
that it is short and easy to complete [26].
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